Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at
Wall Street
Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.